UT Southwestern Medical Center researchers have identified compounds that appear to inhibit a signaling pathway in Huntington’s disease, a finding that may eventually lead to a potential drug therapy to help slow the progression of degenerative nerve disorders. “Our studies have uncovered a new therapeutic target for Huntington’s disease treatment and possibly for other neurodegenerative diseases,” said Dr. Ilya Bezprozvanny, professor of physiology and senior author of the study, published in the June 23 issue of Chemistry and Biology. “In addition, we now have this new series of compounds that gives us a tool to study the pathogenesis of Huntington’s disease.”
